Table 4.

Moderate and large effect sizes of differences in symptom severity means of patients with CML treated with different TKIs

	Drug 1, mean (SD)	Drug 2, mean (SD)	Difference	Effect size
Imatinib (drug 1) vs nilotinib (drug 2)
Nausea	1.03 (1.64)	0.41 (1.10)	0.62	0.40
Dry mouth	1.94 (2.31)	1.14 (2.10)	0.81	0.36
Numbness and tingling	1.49 (2.01)	0.91 (1.54)	0.58	0.31
Diarrhea	1.68 (2.37)	0.55 (1.37)	1.13	0.52
Swelling	2.17 (2.08)	1.18 (1.71)	0.99	0.49
Muscle soreness	2.55 (2.54)	1.59 (2.30)	0.96	0.39
Mean CML-module items	1.75 (1.45)	1.20 (1.46)	0.55	0.38
Mean 5 most severe symptoms	2.39 (2.05)	1.73 (1.84)	0.66	0.33
Imatinib (drug 1) vs dasatinib (drug 2)
Nausea	1.03 (1.64)	0.44 (1.52)	0.59	0.37
Distress	1.73 (2.31)	1.03 (1.59)	0.70	0.33
Lack of appetite	0.73 (1.52)	0.18 (0.52)	0.56	0.43
Dry mouth	1.94 (2.31)	1.26 (1.91)	0.68	0.31
Feeling drowsy	2.44 (2.42)	1.53 (1.66)	0.91	0.41
Muscle soreness	2.55 (2.54)	1.68 (2.31)	0.87	0.35
Mean all symptom items	1.66 (1.41)	1.42 (1.96)	0.48	0.38
Mean CML-module Items	1.75 (1.45)	1.08 (1.01)	0.66	0.50
Dasatinib (drug 1) vs nilotinib (drug 2)
Distress	1.03 (1.59)	1.86 (2.23)	0.83	0.45
Vomiting	0.09 (0.29)	0.50 (1.41)	0.41	0.45
Headache	0.56 (0.93)	1.19 (1.78)	0.63	0.48